# A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

> **NCT04791514** · PHASE2 · TERMINATED · sponsor: **Insmed Incorporated** · enrollment: 1 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Treprostinil Palmitil

## Key facts

- **NCT ID:** NCT04791514
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-29
- **Primary completion:** 2022-08-26
- **Final completion:** 2022-08-26
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Low enrolment
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04791514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04791514, "A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04791514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*